Disease · EFO_0003776

coronary artery bypass

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. coronary artery bypass. Diseases, record EFO_0003776. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0003776

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: coronary artery bypass; Open Targets
Open Targets ID: EFO_0003776; Open Targets
Other names: Aortocoronary Bypass, Aortocoronary Bypasses, Artery Bypass, Coronary, Artery Bypasses, Coronary, BYPASS SURG CORONARY ARTERY, Bypass Surgery, Coronary Artery, Bypass, Aortocoronary, Bypass, Coronary Artery, Bypasses, Aortocoronary, Bypasses, Coronary Artery, CABG, CORONARY ARTERY BYPASS SURG, Coronary Artery Bypass Grafting, Coronary Artery Bypass Surgery, Coronary Artery Bypasses; Open Targets
MeSH: D001026; MeSH
NCI Thesaurus: C51998; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 2 of its 13 drugs, from ClinicalTrials.gov; Open Targets

Drugs13

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BIVALIRUDIN	CHEMBL5314348	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SODIUM LACTATE	CHEMBL1357	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
THIAMINE	CHEMBL1588	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PROPOFOL	CHEMBL526	Small molecule	Phase 1/2	ClinicalTrials.gov	2	2	2	Drugs and targets
SEVOFLURANE	CHEMBL1200694	Small molecule	Phase 1/2	ClinicalTrials.gov	2	2	2	Drugs and targets
DEXMEDETOMIDINE	CHEMBL778	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
METHYLPREDNISOLONE	CHEMBL650	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
ASPIRIN	CHEMBL25	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
CLOPIDOGREL	CHEMBL1771	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
HETASTARCH	CHEMBL2108448		Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 13

See all 13 drugs

Targets32

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GABRA1	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Phase 1/2	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Phase 1/2	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Phase 1/2	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Phase 1/2	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Phase 1/2	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Phase 1/2	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Phase 1/2	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Phase 1/2	https://conductscience.org/library/genes/2561	Drugs and targets
GABRB3	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Phase 1/2	https://conductscience.org/library/genes/2562	Drugs and targets
GABRD	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Phase 1/2	https://conductscience.org/library/genes/2563	Drugs and targets

1 to 10 of 32

See all 32 targets

Trials9

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02322892	Thiamine as an Adjunctive Therapy in Cardiac Surgery	Phase 2	64	2017-03-30	Coronary Artery Bypass, Cardiac Surgical Procedures	THIAMINE	Its record names the disease	ClinicalTrials.gov
NCT02329158	Disinvestment in Hydroxyl-ethyl Starches (HES) for Cardiac Surgery		2,000		Cardiac Surgical Procedures	HETASTARCH	Its record names the disease	ClinicalTrials.gov
NCT06496165	Remimazolam Besylate and Propofol Sedation on Hemodynamic for Coronary Artery Bypass Graft Patients	Not applicable	338		Coronary Artery Disease	PROPOFOL, REMIMAZOLAM BESYLATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00079586	Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)	Phase 3	150		Cardiovascular Disease, Coronary Artery Bypass Surgery	BIVALIRUDIN	Its record names the disease	ClinicalTrials.gov
NCT00484575	Inhaled Sevoflurane Compared to Intravenous Sedation Post Coronary Artery Bypass Grafting	Phase 1/2	100		Myocardial Reperfusion Injury, Atrial Fibrillation	PROPOFOL, SEVOFLURANE	Its record names the disease	ClinicalTrials.gov
NCT07313969	Ultra-Low-Flow Anesthesia and Carbon Footprint	Not applicable	92		Low Flow Anesthesia, Sevoflurane Anesthesia, Cardiac Surgery	SEVOFLURANE	Its record names the disease	ClinicalTrials.gov
NCT01871935	Atropine Effects in Anaesthesia With Sufentanil vs. Remifentanil	Not applicable	70		Haemodynamic Fluctuations During Off-pump CABG.	REMIFENTANIL, SUFENTANIL	Its record names the disease	ClinicalTrials.gov
NCT07101367	A Comparative Study Between Dexmedetomidine Versus Methylprednisolone on Induced Inflammatory Response in Patients Undergoing On-pump CABG	Phase 1/2	60		Coronary Artery Disease, Systemic Inflammatory Response Syndrome, Postoperative Complications	DEXMEDETOMIDINE, METHYLPREDNISOLONE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00262275	Optimum Platelet Inhibition After Coronary Bypass Surgery	Not applicable			Ischemic Heart Disease	ASPIRIN, CLOPIDOGREL	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Thiamine vs Control Arm: Mortality	0 of 31	1 of 33	64	NCT02322892	Trial comparisons
Thiamine vs Control Arm: Patients With Post-operative Complications	16 of 31	16 of 33	64	NCT02322892	Trial comparisons
Thiamine vs Control Arm: serious adverse events	0 of 31	0 of 33	64	NCT02322892	Trial comparisons

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
16716214	RESULT	1	PubMed
15354104	RESULT	1	PubMed
33028197	DERIVED	1	PubMed
30411246	DERIVED	1	PubMed
27044557	DERIVED	1	PubMed
17184645	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0003776

GET https://conductscience.org/api/diseases/v1/EFO_0003776/targets?page=2

API reference For AI assistants